CIRB #pend/ NRG #GY005: A Randomized Phase II/III Study of The Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) (not yet submitted to IRB)

Primary teaching affiliate
of BU School of Medicine